In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lexicon Pharmaceuticals Inc.

www.lexpharma.com

Latest From Lexicon Pharmaceuticals Inc.

New EU Approvals

The Pink Sheet’s list of EU centralized approvals of new active substances now includes five new products, one of which is BioMarin Pharmaceutical's Palynziq for treating phenylketonuria. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

Approvals Europe

Benefits Outweigh Risks As Europe Okays Sanofi’s Zynquista, Despite Unresolved FDA CRL

As the US approval of Sanofi’s type 1 diabetes drug looks to be likely pushed back for another two years, EU approval means the drug can begin to gain market share on the other side of the Atlantic.

Europe Approvals

AZ's Forxiga Gets Type 1 Diabetes EU Okay As Sanofi Suffers US Setback

Forxiga is the first oral medicine approved in the EU as an adjunct to insulin for type 1 diabetes and the regulatory boost for AstraZeneca comes as Sanofi gets a CRL from the FDA for Zynquista.

Metabolic Disorders Approvals

Keeping Track: Thumbs Up For Zulresso And Sunosi, Thumbs Down For Zynquista And IV Meloxicam

The latest drug development news and highlights from our US FDA Performance Tracker. 
Drug Review Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Lexicon Genetics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Lexicon Pharmaceuticals Inc.
  • Senior Management
  • Lonnel Coats, Pres. & CEO
    Jeffrey L Wade, EVP, CFO
    Praveen Tyle, PhD, EVP, R&D
    Pablo Lapuerta, MD, EVP, CMO
  • Contact Info
  • Lexicon Pharmaceuticals Inc.
    Phone: (281) 863-3000
    8800 Technology Forest Pl.
    The Woodlands, TX 77381-1160
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register